

Data Sharing Statement

The RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2022926.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	Please complete this form https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx and e-mail to: data.access@ndph.ox.ac.uk
When will data availability begin?	Within 3 months of publication.
When will data availability end?	—
Will any supporting documents be available?	Yes
Which supporting documents?	Protocol, consent form, statistical analysis plan, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net
Additional information about supporting documents	—
How or where can supporting documents be obtained?	www.recoverytrial.net
When will supporting documents availability begin?	Immediately via study website
When will supporting documents availability end?	—
To whom will data be available?	The applicant must be a bona fide researcher registered with an appropriate institution.
For what type of analysis or purpose?	Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access

By what mechanism?	Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access
Any other restrictions?	The Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with the relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication.
Additional information	—

This statement was posted on October 8, 2020, at NEJM.org.